Displaying 231–240 of 866 results
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
Jan 5, 2022
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
Jan 5, 2022
Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
Dec 27, 2021
In Memoriam: Dr. Alan Laties – Early Leader in Retinal Research
Dec 22, 2021
Organizations collaborate on inherited macular dystrophy program
The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
Dec 15, 2021
Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseases
Program to have special translational research emphasis on inherited macular dystrophy.
Dec 14, 2021
Eyes On Eyecare Raises $1,500 for Foundation Fighting Blindness
Over 1,400 people participated in charitable giving initiative.
Dec 13, 2021
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
Dec 13, 2021
At only three months old, Brendon was diagnosed with x-linked juvenile retinoschisis (XLRS). But with several other family members also with XLRS, Brendon knew he could still follow his passions for science and space. Now 22, Brendon is an Aerospace Engineer, starting a PhD program at UCF, and was recently awarded the prestigious National Science Foundation’s Graduate Research Fellowship.